The Marion Gluck Clinic

High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.

This study analysed data obtained from a phase III clinical trial involving 218 post-menopausal women with vaginal atrophy who received daily intravaginal DHEA (0.25%, 0.5% or 1.0%) for a 12-week period. One of the main findings was that the 0.5% DHEA daily intravaginal dose was found to have a ‘statistically significant’ to ‘highly significant’ effect on all parameters of vaginal atrophy. It was also found to not significantly affect the serum levels of estrogens, further emphasising its clinical effectiveness.

Balance Health Energy